US6924128B2
(en)
|
1994-12-06 |
2005-08-02 |
Targeted Genetics Corporation |
Packaging cell lines for generation of high titers of recombinant AAV vectors
|
JP4289687B2
(ja)
|
1997-03-14 |
2009-07-01 |
ザ チルドレンズ ホスピタル オブ フィラデルフィア |
血友病の治療のための遺伝子治療で使用する方法と組成物
|
US6566118B1
(en)
|
1997-09-05 |
2003-05-20 |
Targeted Genetics Corporation |
Methods for generating high titer helper-free preparations of released recombinant AAV vectors
|
US6995006B2
(en)
|
1997-09-05 |
2006-02-07 |
Targeted Genetics Corporation |
Methods for generating high titer helper-free preparations of released recombinant AAV vectors
|
CA2324225A1
(en)
*
|
1998-03-20 |
1999-09-23 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for helper-free production of recombinant adeno-associated viruses
|
US6953690B1
(en)
|
1998-03-20 |
2005-10-11 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for helper-free production of recombinant adeno-associated viruses
|
US6436392B1
(en)
|
1998-05-20 |
2002-08-20 |
University Of Iowa Research Foundation |
Adeno-associated virus vectors
|
EP1849872A1
(de)
*
|
1998-05-20 |
2007-10-31 |
University Of Iowa Research Foundation |
Adenoassoziierte Virusvektoren und ihre Verwendung
|
DE19905501B4
(de)
|
1999-02-10 |
2005-05-19 |
MediGene AG, Gesellschaft für molekularbiologische Kardiologie und Onkologie |
Verfahren zur Herstellung eines rekombinanten Adeno-assoziierten Virus, geeignete Mittel hierzu sowie Verwendung zur Herstellung eines Arzneimittels
|
US6258595B1
(en)
|
1999-03-18 |
2001-07-10 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for helper-free production of recombinant adeno-associated viruses
|
JP4693244B2
(ja)
|
1999-03-18 |
2011-06-01 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
組換えアデノ随伴ウイルスのヘルパー無しの生産のための組成物および方法
|
US6893865B1
(en)
|
1999-04-28 |
2005-05-17 |
Targeted Genetics Corporation |
Methods, compositions, and cells for encapsidating recombinant vectors in AAV particles
|
AU782966B2
(en)
|
1999-06-08 |
2005-09-15 |
University Of Iowa Research Foundation, The |
Compounds and methods to enhance RAAV transduction
|
US7122335B1
(en)
|
1999-06-08 |
2006-10-17 |
University Of Iowa Research Foundation |
Compounds and methods to enhance rAAV transduction
|
US7241447B1
(en)
|
1999-10-07 |
2007-07-10 |
University Of Iowa Research Foundation |
Adeno-associated virus vectors and uses thereof
|
JP2003533170A
(ja)
*
|
1999-10-07 |
2003-11-11 |
ユニバーシテイ・オブ・アイオワ・リサーチ・フアウンデーシヨン |
アデノ随伴ウイルスおよびその使用
|
JP2004514407A
(ja)
|
2000-04-28 |
2004-05-20 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
異種キャプシド中にシュードタイピングされたaav5キャプシドおよびaav5ベクターを含む組換えaavベクター
|
WO2001083695A2
(en)
|
2000-04-28 |
2001-11-08 |
Xiao Xiao |
Dna sequences encoding dystrophin minigenes and methods of use thereof
|
US8241622B2
(en)
|
2001-07-13 |
2012-08-14 |
University Of Iowa Research Foundation |
Adeno-associated virus vectors with intravector heterologous terminal palindromic sequences
|
NZ600121A
(en)
|
2001-11-13 |
2013-12-20 |
Univ Pennsylvania |
A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
|
DK2359869T3
(en)
|
2001-12-17 |
2019-04-15 |
Univ Pennsylvania |
Sequences of adeno-associated virus (AAV) serotype 8, vectors containing these, and uses thereof
|
ES2664505T3
(es)
|
2001-12-17 |
2018-04-19 |
The Trustees Of The University Of Pennsylvania |
Secuencias de serotipo 9 de virus adeno-asociado (AAV), vectores que las contienen, y usos de las mismas
|
CA2520028A1
(en)
|
2003-03-31 |
2004-10-21 |
University Of Iowa Research Foundation |
Compounds and methods to enhance raav transduction
|
SI2292780T1
(sl)
|
2003-09-30 |
2017-12-29 |
The Trustees Of The University Of Pennsylvania |
Genotipske skupine, zaporedja, vektorji, ki vsebujejo le-te z adenovirusi povezanega virusa (aav) in njihova uporaba
|
WO2006033672A2
(en)
|
2004-04-28 |
2006-03-30 |
The Trustees Of The University Of Pennsylvania |
Immunization regimen with e4-deleted adenovirus prime and e1-deleted adenovirus boost
|
US8394386B2
(en)
|
2004-04-28 |
2013-03-12 |
The Trustees Of The University Of Pennsylvania |
Sequential delivery of immunogenic molecules via adenovirus and adeno-associated virus-mediated administrations
|
CN1286981C
(zh)
*
|
2004-11-30 |
2006-11-29 |
华中科技大学同济医学院附属同济医院 |
表达人类cyp2j2反义基因的重组腺相关病毒及其制备方法
|
CN100374572C
(zh)
*
|
2005-07-19 |
2008-03-12 |
北京市肿瘤防治研究所 |
一种体外培养骨骼肌表达体系
|
EP2679237A1
(de)
|
2006-11-29 |
2014-01-01 |
Nationwide Children's Hospital |
Myostatinhemmung zur Verstärkung und/oder Verbesserung der Muskelfunktion
|
US11219696B2
(en)
|
2008-12-19 |
2022-01-11 |
Nationwide Children's Hospital |
Delivery of polynucleotides using recombinant AAV9
|
US9415121B2
(en)
|
2008-12-19 |
2016-08-16 |
Nationwide Children's Hospital |
Delivery of MECP2 polynucleotide using recombinant AAV9
|
AU2011332815A1
(en)
|
2010-11-23 |
2013-05-30 |
Presage Biosciences, Inc. |
Therapeutic methods and compositions for solid delivery
|
US10196636B2
(en)
|
2011-04-21 |
2019-02-05 |
Nationwide Children's Hospital, Inc. |
Recombinant virus products and methods for inhibition of expression of myotilin
|
CA2839773C
(en)
|
2011-04-21 |
2021-03-30 |
Nationwide Children's Hospital, Inc. |
Recombinant virus products and methods for inhibition of expression of myotilin
|
US20130039888A1
(en)
|
2011-06-08 |
2013-02-14 |
Nationwide Children's Hospital Inc. |
Products and methods for delivery of polynucleotides by adeno-associated virus for lysosomal storage disorders
|
AU2012286994B2
(en)
|
2011-07-25 |
2017-08-10 |
Nationwide Children's Hospital, Inc. |
Recombinant virus products and methods for inhibition of expression of DUX4
|
US9434928B2
(en)
|
2011-11-23 |
2016-09-06 |
Nationwide Children's Hospital, Inc. |
Recombinant adeno-associated virus delivery of alpha-sarcoglycan polynucleotides
|
JP6314138B2
(ja)
|
2012-08-01 |
2018-04-18 |
ネイションワイド チルドレンズ ホスピタル |
組換えアデノ随伴ウイルス9の髄腔内送達
|
CA2885216A1
(en)
|
2012-09-17 |
2014-03-20 |
The Research Institute At Nationwide Children's Hospital |
Compositions and methods for treating amyotrophic lateral sclerosis
|
DK3889173T3
(da)
|
2013-02-15 |
2023-10-09 |
Bioverativ Therapeutics Inc |
Optimeret faktor viii-gen
|
MX2015014712A
(es)
|
2013-04-20 |
2016-04-27 |
Res Inst Nationwide Childrens Hospital |
Administración de virus adeno-asociado recombinante de construcciones de polinucléotidos u7snrna dirigida al exon 2.
|
ES2936220T3
(es)
|
2013-08-27 |
2023-03-15 |
Res Inst Nationwide Childrens Hospital |
Productos y métodos para el tratamiento de la esclerosis lateral amiotrófica
|
JP2016538276A
(ja)
|
2013-11-05 |
2016-12-08 |
ザ・リサーチ・インスティテュート・アット・ネイションワイド・チルドレンズ・ホスピタルThe Research Institute At Nationwide Children’S Hospital |
筋萎縮性側索硬化症の処置のためのNF−κBおよびSOD−1を阻害する組成物および方法
|
KR102390075B1
(ko)
|
2014-03-09 |
2022-04-26 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
오르니틴 트랜스카르바밀라아제(otc) 결핍증의 치료에 유용한 조성물
|
US10577627B2
(en)
|
2014-06-09 |
2020-03-03 |
Voyager Therapeutics, Inc. |
Chimeric capsids
|
WO2016004113A1
(en)
|
2014-06-30 |
2016-01-07 |
Biogen Ma Inc. |
Optimized factor ix gene
|
WO2016025339A2
(en)
|
2014-08-09 |
2016-02-18 |
Research Institute At Nationwide Children's Hospital |
Methods and materials for activating an internal ribosome entry site in exon 5 of the dmd gene
|
WO2016057975A2
(en)
|
2014-10-10 |
2016-04-14 |
Research Institute At Nationwide Children's Hospital |
Guided injections for aav gene transfer to muscle
|
MX2017005834A
(es)
|
2014-11-05 |
2017-11-17 |
Voyager Therapeutics Inc |
Polinucleotidos aad para el tratamiento de la enfermedad de parkinson.
|
CA2966884A1
(en)
|
2014-11-05 |
2016-05-12 |
Research Institute At Nationwide Children's Hospital |
Methods and materials for producing recombinant viruses in eukaryotic microalgae
|
RU2749882C2
(ru)
|
2014-11-14 |
2021-06-18 |
Вояджер Терапьютикс, Инк. |
Модулирующие полинуклеотиды
|
KR102599909B1
(ko)
|
2014-11-14 |
2023-11-09 |
보이저 테라퓨틱스, 인크. |
근위축성 측삭 경화증(als)을 치료하는 조성물 및 방법
|
EP3230441A4
(de)
|
2014-12-12 |
2018-10-03 |
Voyager Therapeutics, Inc. |
Zusammensetzungen und verfahren zur herstellung von scaav
|
AU2016323575B2
(en)
|
2015-09-17 |
2022-10-27 |
Research Institute At Nationwide Children's Hospital |
Methods and materials for GALGT2 gene therapy
|
EP3370778A1
(de)
|
2015-11-05 |
2018-09-12 |
Bamboo Therapeutics, Inc. |
Modifizierte friedreich-ataxie-gene und vektoren zur gentherapie
|
CA3006569A1
(en)
|
2015-12-02 |
2017-06-08 |
Voyager Therapeutics, Inc. |
Assays for the detection of aav neutralizing antibodies
|
PT3411478T
(pt)
|
2016-02-01 |
2022-09-13 |
Bioverativ Therapeutics Inc |
Genes do fator viii otimizados
|
WO2017139381A1
(en)
|
2016-02-08 |
2017-08-17 |
University Of Iowa Research Foundation |
Methods to produce chimeric adeno-associated virus/bocavirus parvovirus
|
EP3420109A4
(de)
|
2016-02-26 |
2019-11-06 |
Research Institute at Nationwide Children's Hospital |
Rekombinante virusprodukte und verfahren zur induktion von dux4-exon-skipping
|
AU2017229347A1
(en)
|
2016-03-07 |
2018-11-01 |
University Of Iowa Research Foundation |
AAV-mediated expression using a synthetic promoter and enhancer
|
KR102453187B1
(ko)
|
2016-04-02 |
2022-10-07 |
더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 |
조직 특이적 발현을 위한 변형된 u6 프로모터 시스템
|
RS65490B1
(sr)
|
2016-04-15 |
2024-05-31 |
Res Inst Nationwide Childrens Hospital |
Vektor adeno-asociranog virusa za isporuku β-sarkoglikana i mikrorna-29 i tretman mišićne distrofije
|
MA45477A
(fr)
|
2016-04-15 |
2019-02-20 |
Res Inst Nationwide Childrens Hospital |
Administration à vecteurs de virus adéno-associé de microarn-29 et micro-dystrophine pour traiter la dystrophie musculaire
|
WO2017189959A1
(en)
|
2016-04-29 |
2017-11-02 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
WO2017189964A2
(en)
|
2016-04-29 |
2017-11-02 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
SG11201809643UA
(en)
|
2016-05-18 |
2018-12-28 |
Voyager Therapeutics Inc |
Compositions and methods of treating huntington's disease
|
IL302748A
(en)
|
2016-05-18 |
2023-07-01 |
Voyager Therapeutics Inc |
modulatory polynucleotides
|
AU2017321488B2
(en)
|
2016-08-30 |
2022-10-20 |
The Regents Of The University Of California |
Methods for biomedical targeting and delivery and devices and systems for practicing the same
|
AU2017362491B2
(en)
|
2016-11-17 |
2023-02-02 |
Nationwide Children's Hospital Inc. |
Intrathecal delivery of recombinant Adeno-associated virus encoding Methyl-CpG binding protein 2
|
WO2018132747A1
(en)
|
2017-01-13 |
2018-07-19 |
University Of Iowa Research Foundation |
Bocaparvovirus small noncoding rna and uses thereof
|
MA47800A
(fr)
|
2017-03-17 |
2020-01-22 |
Univ Newcastle |
Délivrance par vecteur viral adéno-associé d'un fragment de micro-dystrophine pour traiter la dystrophie musculaire
|
LT3596222T
(lt)
|
2017-03-17 |
2023-07-25 |
Research Institute At Nationwide Children's Hospital |
Raumeniui specifinis mikrodistrofino pristatymas adenoasocijuoto viruso vektoriaus dėka, skirtas raumenų distrofijai gydyti
|
MX2019013172A
(es)
|
2017-05-05 |
2020-09-07 |
Voyager Therapeutics Inc |
Composiciones y metodos para tratar la enfermedad de huntington.
|
WO2018204786A1
(en)
|
2017-05-05 |
2018-11-08 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating amyotrophic lateral sclerosis (als)
|
JOP20190269A1
(ar)
|
2017-06-15 |
2019-11-20 |
Voyager Therapeutics Inc |
بولي نوكليوتيدات aadc لعلاج مرض باركنسون
|
CA3068906A1
(en)
|
2017-07-08 |
2019-01-17 |
Genethon |
Treatment of spinal muscular atrophy
|
CN111132626B
(zh)
|
2017-07-17 |
2024-01-30 |
沃雅戈治疗公司 |
轨迹阵列引导***
|
EP3662060A2
(de)
|
2017-08-03 |
2020-06-10 |
Voyager Therapeutics, Inc. |
Zusammensetzungen und verfahren zur aav-freisetzung
|
EP3697908A1
(de)
|
2017-10-16 |
2020-08-26 |
Voyager Therapeutics, Inc. |
Behandlung von amyotropher lateralsklerose (als)
|
TWI804518B
(zh)
|
2017-10-16 |
2023-06-11 |
美商航海家醫療公司 |
肌萎縮性脊髓側索硬化症(als)之治療
|
WO2019078916A1
(en)
|
2017-10-18 |
2019-04-25 |
Research Institute At Nationwide Children's Hospital |
ADENO-ASSOCIATED VIRUS VECTOR ADMINISTRATION OF MUSCLE-SPECIFIC MICRO-DYSTROPHINE TO TREAT MUSCLE DYSTROPHY
|
SG11202003285PA
(en)
|
2017-10-20 |
2020-05-28 |
Res Inst Nationwide Childrens Hospital |
Methods and materials for nt-3 gene therapy
|
CA3103485A1
(en)
|
2018-06-18 |
2019-12-26 |
Research Institute At Nationwide Children's Hospital |
Adeno-associated virus vector delivery of muscle specific micro-dystrophin to treat muscular dystrophy
|
EP3807309A1
(de)
|
2018-06-18 |
2021-04-21 |
Research Institute at Nationwide Children's Hospital |
Rekombinante adeno-assoziierte virusprodukte und verfahren zur behandlung von dystroglycanopathien und von laminindefizienten muskeldystrophien
|
US20210277362A1
(en)
|
2018-06-29 |
2021-09-09 |
Research Institute At Nationwide Children's Hospital |
Recombinant adeno-associated virus products and methods for treating limb girdle muscular dystrophy 2a
|
WO2020047268A1
(en)
|
2018-08-29 |
2020-03-05 |
Research Institute At Nationwide Children's Hospital |
Products and methods for inhibition of expression of mutant gars protein
|
WO2020068990A1
(en)
|
2018-09-26 |
2020-04-02 |
California Institute Of Technology |
Adeno-associated virus compositions for targeted gene therapy
|
AU2019346655A1
(en)
*
|
2018-09-28 |
2021-05-06 |
Voyager Therapeutics, Inc. |
Frataxin expression constructs having engineered promoters and methods of use thereof
|
CA3122319A1
(en)
|
2018-12-21 |
2020-06-25 |
Genethon |
Expression cassettes for gene therapy vectors
|
AU2019419494A1
(en)
|
2018-12-31 |
2021-07-15 |
Research Institute At Nationwide Children's Hospital |
DUX4 RNA silencing using RNA targeting CRISPR-Cas13b
|
SG11202107986YA
(en)
|
2019-02-04 |
2021-08-30 |
Res Inst Nationwide Childrens Hospital |
Adeno-associated virus delivery of cln3 polynucleotide
|
EP3921429A1
(de)
|
2019-02-04 |
2021-12-15 |
Research Institute at Nationwide Children's Hospital |
Adeno-assoziierte virusfreisetzung von cln6-polynukleotid
|
TW202045531A
(zh)
|
2019-02-26 |
2020-12-16 |
美國全美兒童醫院之研究學會 |
Β-肌聚糖之腺相關病毒載體遞送及肌肉營養不良症之治療
|
US20220193259A1
(en)
|
2019-04-15 |
2022-06-23 |
Sanford Research |
Gene therapy for treating or preventing visual effects in batten disease
|
US20220226507A1
(en)
|
2019-05-17 |
2022-07-21 |
Research Institute At Nationwide Children's Hospital |
Optimized gene therapy targeting retinal cells
|
LT4017871T
(lt)
|
2019-08-21 |
2024-05-10 |
Research Institute At Nationwide Children's Hospital |
Alfa-sarkoglikano pristatymas adeno-asocijuoto viruso vektoriumi ir raumenų distrofijos gydymas
|
EP4045662A1
(de)
|
2019-10-18 |
2022-08-24 |
Research Institute at Nationwide Children's Hospital |
Materialien und verfahren zur behandlung von krankheiten, die mit mutationen im irf2bpl-gen einhergehen
|
CA3158286A1
(en)
|
2019-10-18 |
2021-04-22 |
Research Institute At Nationwide Children's Hospital |
Gene therapy targeting cochlear cells
|
TW202130812A
(zh)
*
|
2019-11-01 |
2021-08-16 |
美商聖加莫治療股份有限公司 |
用於基因體工程之組合物及方法
|
IL293210A
(en)
|
2019-11-22 |
2022-07-01 |
Res Inst Nationwide Childrens Hospital |
Materials and methods for treating disorders associated with the ighmbp2 gene
|
WO2021127655A1
(en)
|
2019-12-20 |
2021-06-24 |
Research Institute At Nationwide Children's Hospital |
Optimized gene therapy for targeting muscle in muscle diseases
|
EP4107266A1
(de)
|
2020-02-18 |
2022-12-28 |
Research Institute at Nationwide Children's Hospital |
Aav-vermitteltes targeting von mirna bei der behandlung von x-assoziierten erkrankungen
|
CA3174863A1
(en)
|
2020-04-14 |
2021-10-21 |
Ana BUJ BELLO |
Vectors for the treatment of acid ceramidase deficiency
|
WO2021257595A1
(en)
|
2020-06-15 |
2021-12-23 |
Research Institute At Nationwide Children's Hospital |
Adeno-associated virus vector delivery for muscular dystrophies
|
TW202227634A
(zh)
|
2020-09-08 |
2022-07-16 |
美商薩羅塔治療公司 |
表現γ—肌聚醣之腺相關病毒載體之全身性遞送及肌肉失養症之治療
|
EP4214317A2
(de)
|
2020-09-15 |
2023-07-26 |
Research Institute at Nationwide Children's Hospital |
Aav-vermittelte homologieunabhängige gezielte integrationsgeneditierung zur korrektur verschiedener dmd-mutationen bei patienten mit muskeldystrophie
|
EP4217375A1
(de)
|
2020-09-28 |
2023-08-02 |
Research Institute at Nationwide Children's Hospital |
Produkte und verfahren zur behandlung von muskeldystrophie
|
WO2022097008A1
(en)
|
2020-11-03 |
2022-05-12 |
Pfizer Inc. |
Methods for purification of aav vectors by anion exchange chromatography
|
CA3203585A1
(en)
|
2020-11-30 |
2022-06-02 |
Research Institute At Nationwide Children's Hospital |
Compositions and methods for treating facioscapulohumeral muscular dystrophy (fshd)
|
MX2023007612A
(es)
|
2020-12-23 |
2023-07-12 |
Pfizer |
Metodos para purificacion de vectores aav por cromatografia de afinidad.
|
EP4284413A1
(de)
|
2021-01-27 |
2023-12-06 |
Research Institute at Nationwide Children's Hospital |
Materialien und verfahren zur behandlung von lysosomaler saurer lipase (lal-d)
|
WO2022169922A1
(en)
|
2021-02-03 |
2022-08-11 |
Research Institute At Nationwide Children's Hospital |
Compositions and methods for treating disease associated with dux4 overexpression
|
WO2022170038A1
(en)
|
2021-02-05 |
2022-08-11 |
Amicus Therapeutics, Inc. |
Adeno-associated virus delivery of cln3 polynucleotide
|
US11760788B2
(en)
|
2021-03-02 |
2023-09-19 |
Pathways Neuro Pharma, Inc. |
Neuroreceptor compositions and methods of use
|
WO2022187571A1
(en)
|
2021-03-04 |
2022-09-09 |
Research Institute At Nationwide Children's Hospital |
Products and methods for treatment of dystrophin-based myopathies using crispr-cas9 to correct dmd exon duplications
|
WO2022208342A1
(en)
|
2021-04-01 |
2022-10-06 |
Pfizer Inc. |
Pharmaceutical compositions containing adeno-associated viral vector
|
US20240189452A1
(en)
|
2021-04-13 |
2024-06-13 |
Research Institute At Nationwide Children's Hospital |
Recombinant Adeno-Associated Virus Encoding Methyl-CPG Binding Protein 2 for Treating PITT Hopkins Syndrome VIA Intrathecal Delivery
|
WO2022221420A2
(en)
|
2021-04-13 |
2022-10-20 |
Capsida, Inc. |
Selected aav compositions having preferred brain enrichment
|
EP4326752A1
(de)
|
2021-04-23 |
2024-02-28 |
Research Institute at Nationwide Children's Hospital |
Produkte und verfahren zur behandlung von muskeldystrophie
|
EP4329820A1
(de)
|
2021-04-26 |
2024-03-06 |
Alexion Pharma International Operations Limited |
Adeno-assoziierte virale vektorkapside mit verbessertem gewebetropismus
|
IL308431A
(en)
|
2021-05-17 |
2024-01-01 |
Sarepta Therapeutics Inc |
Production of recombinant AAV vectors for the treatment of muscular dystrophy
|
EP4108263A3
(de)
|
2021-06-02 |
2023-03-22 |
Research Institute at Nationwide Children's Hospital |
Rekombinante adeno-assoziierte virusprodukte und verfahren zur behandlung von gliedergürtel-muskeldystrophie 2a
|
KR20240095165A
(ko)
|
2021-08-11 |
2024-06-25 |
솔리드 바이오사이언시즈 인크. |
근이영양증의 치료
|
WO2023060215A1
(en)
|
2021-10-07 |
2023-04-13 |
Research Institute At Nationwide Children's Hospital |
Products and methods for myelin protein zero silencing and treating cmt1b disease
|
WO2023060233A1
(en)
|
2021-10-08 |
2023-04-13 |
Amicus Therapeutics, Inc. |
Biomarkers for lysosomal storage diseases
|
US20230139985A1
(en)
|
2021-10-15 |
2023-05-04 |
Research Institute At Nationwide Children's Hospital |
Self-Complementary Adeno-Associated Virus Vector and its Use in Treatment of Muscular Dystrophy
|
US20230279431A1
(en)
|
2021-11-30 |
2023-09-07 |
Research Institute At Nationwide Children's Hospital |
Self-Complementary Adeno-Associated Virus Vector and its Use in Treatment of Muscular Dystrophy
|
EP4198047A1
(de)
|
2021-12-16 |
2023-06-21 |
Genethon |
Erhöhung des gentransfers von fukutin-verwandtem protein unter verwendung modifizierter itr-sequenzen
|
EP4198048A1
(de)
|
2021-12-16 |
2023-06-21 |
Genethon |
Calpain-3-gentransfersteigerung unter verwendung von modifizierten itr-sequenzen
|
EP4198046A1
(de)
|
2021-12-16 |
2023-06-21 |
Genethon |
Erhöhung des gentransfers von alpha-sarcoglykan unter verwendung von modifizierten itr-sequenzen
|
EP4198134A1
(de)
|
2021-12-16 |
2023-06-21 |
Genethon |
Transfererhöhung des gamma-sarcoglycan-gens unter verwendung von modifizierten itr-sequenzen
|
AU2022420596A1
(en)
|
2021-12-21 |
2024-07-11 |
Research Institute At Nationwide Children's Hospital |
Materials and methods for the treatment of limb girdle muscular dystrophy
|
WO2023168400A2
(en)
|
2022-03-03 |
2023-09-07 |
Research Institute At Nationwide Children's Hospital |
Materials and methods for the treatment of eif2b5 mutations and diseases resulting therefrom
|
WO2023240177A1
(en)
|
2022-06-08 |
2023-12-14 |
Research Instiitute At Nationwide Children's Hospital |
Products and methods for treating diseases or conditions associated with mutant or pathogenic kcnq3 expression
|
WO2024003687A1
(en)
|
2022-06-28 |
2024-01-04 |
Pfizer Inc. |
Nucleic acids encoding acid alpha-glucosidase (gaa) and vectors for gene therapy
|
WO2024011115A1
(en)
|
2022-07-06 |
2024-01-11 |
Research Institute At Nationwide Children's Hospital |
Adeno-associated virus delivery of cln1 polynucleotide
|
WO2024035782A1
(en)
|
2022-08-10 |
2024-02-15 |
Aav Gene Therapeutics, Inc. |
Aav-mediated intramuscular delivery of insulin
|
WO2024038365A1
(en)
|
2022-08-16 |
2024-02-22 |
Pfizer Inc. |
Methods for purification of aav vectors by anion exchange chromatography
|
WO2024064913A1
(en)
|
2022-09-23 |
2024-03-28 |
Sarepta Therapeutics, Inc. |
Recombinant aav vectors for treating muscular dystrophy
|
WO2024081706A1
(en)
|
2022-10-11 |
2024-04-18 |
Research Institute At Nationwide Children's Hospital |
Adeno-associated virus delivery to treat spinal muscular atrophy with respiratory distress type 1 (smard1) and charcot-marie-tooth type 2s (cmt2s)
|
WO2024151982A1
(en)
|
2023-01-13 |
2024-07-18 |
Amicus Therapeutics, Inc. |
Gene therapy constructs for the treatment of pompe disease
|